Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time

Rhea-AI Summary

Senseonics Holdings, Inc. (SENS) will release its Q4 and full year 2023 financial results on February 29, 2024. A conference call will be held to review the performance, with a webcast available on the company's website. Investors and analysts can dial in to listen.

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.

Management will hold a conference call to review the Company’s fourth quarter and full year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 3711982, approximately ten to five minutes prior to start time.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240215367533/en/

Investor Contact

Philip Taylor

Gilmartin Group

415-937-5406

Investors@senseonics.com

Source: Senseonics Holdings, Inc.

FAQ

When will Senseonics Holdings, Inc. (SENS) release its Q4 and full year 2023 financial results?

Senseonics Holdings, Inc. (SENS) will release its Q4 and full year 2023 financial results after market close on Thursday, February 29, 2024.

What is the focus of Senseonics Holdings, Inc. (SENS)?

Senseonics Holdings, Inc. (SENS) is a medical technology company focused on developing long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes.

How can investors access the conference call to review Senseonics Holdings, Inc. (SENS) performance?

Investors can access the conference call to review Senseonics Holdings, Inc. (SENS) performance by dialing 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International) with passcode 3711982, approximately ten to five minutes prior to the start time.

Where can the webcast of Senseonics Holdings, Inc. (SENS) conference call be found?

The webcast of Senseonics Holdings, Inc. (SENS) conference call can be found on the company's website at www.senseonics.com under 'Investor Relations' and then 'Events & Publications'.

Will the webcast of Senseonics Holdings, Inc. (SENS) conference call be available for future reference?

Yes, the webcast of Senseonics Holdings, Inc. (SENS) conference call will be archived on the company's website for future reference.